Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT00884741 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

637

Enrollment

NIH

Sponsor class

Conditions

Glioblastoma
Gliosarcoma
Supratentorial Glioblastoma

Interventions

RADIATION: 3-Dimensional Conformal Radiation Therapy
BIOLOGICAL: Bevacizumab
RADIATION: Intensity-Modulated Radiation Therapy
OTHER: Laboratory Biomarker Analysis
OTHER: Placebo
OTHER: Quality-of-Life Assessment
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]